Find Clinical Trials & Studies
Scleroderma Phase II study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis
I'm Interested!
Please call
1-833-78TRIAL
1-833-78TRIAL
A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis
- Sex: Any
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied:
Study Purpose
The purpose of this study is to evaluate if i.v. rapcabtagene autoleucel (administered once following lymphodepletion) is safe and effective in participants with severe refractory diffuse cutaneous systemic sclerosis.
Who Can Participate
Age: 18-65 years old
- UH IRB: SITE00002502
- StudyID: 2025-01714
- ClinicalTrials.gov: N/A
I'm Interested!
Please call
1-833-78TRIAL
1-833-78TRIAL
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL
Cancer Trials: 1-866-373-1464